BASETEN TARGETS $11B VALUATION IN $1B FUNDING ROUND
AI DESK■ 1 MIN READ
WED, MAY 27, 2026■ AI-SUMMARIZED FROM 1 SOURCE ▸ TIMELINE
AI inference provider Baseten is negotiating to raise $1 billion at an $11 billion post-money valuation, more than doubling its $5 billion valuation from its Series E round in January.
The funding discussions come six months after Baseten closed a $300 million Series E, indicating accelerated investor interest in the AI infrastructure space. The company's valuation would more than double from its previous round, reflecting growing demand for AI inference services as enterprises scale generative AI applications.
Baseten provides infrastructure for running AI models in production, handling the computational workload of executing trained models. The market for such services has intensified as companies seek cost-effective ways to deploy large language models and other AI systems at scale.
The reported funding round has not been officially confirmed by Baseten. The company competes with other inference providers including Modal, Replicate, and cloud providers' native offerings. The shift from $300 million to $1 billion in funding size signals substantial investor confidence in the sector's trajectory, though valuation inflation in AI infrastructure remains a broader market consideration.
■ SOURCES
► Techmeme■ SUMMARY WRITTEN BY AI FROM THE LINKS ABOVE
■ MORE FROM THE STARTUPS DESK
Triomics, an AI platform automating data-heavy tasks for oncologists, secured $22M in Series B funding. The raise follows a $15M Series A in 2024.
12H AGO— AI Desk
Xcena secured $135 million in Series B funding at a $570 million valuation for its MX1 chip, which handles data orchestration and KV cache management directly within memory modules.
12H AGO— AI Desk
Pittsburgh-based Gray Swan, which stress-tests AI models for frontier labs, secured $40M in Series A funding at a $200M valuation. The round was co-led by Wing VC and Madrona.
20H AGO— AI Desk
H1, a healthcare SaaS startup, secured $40 million in funding from CVS Health. The investment signals continued investor confidence in specialized software platforms despite AI disruption concerns.
YESTERDAY— Industry Desk